

**In the claims:**

Please cancel claims 7-12, 15-16, 18-26, 28-56, and 63-195 without prejudice.

1. (previously presented) An antibody or antigen-binding fragment thereof that specifically binds to MGFR.

2. (previously presented) An antibody or antigen-binding fragment thereof as recited in claim 1, wherein the antibody or antigen-binding fragment thereof is bivalent.

3. (previously presented) An antibody or antigen-binding fragment thereof as recited in claim 1, wherein the antibody or antigen-binding fragment thereof is monovalent.

4. (previously presented) An antibody or antigen-binding fragment thereof as recited in claim 1, wherein the antibody or antigen-binding fragment thereof specifically binds to PSMGFR.

5 (previously presented) An antibody or antigen-binding fragment thereof as recited in claim 4, wherein the antibody or antigen-binding fragment thereof specifically binds to the amino acid sequence set forth in SEQ ID NO: 36 or a functional variant or fragment thereof comprising up to 15 amino acid additions or deletions at its N-terminus and comprising up to 20 amino acid substitutions.

6. (previously presented) An antibody or antigen-binding fragment thereof as recited in claim 5, wherein the antibody or antigen-binding fragment thereof specifically binds to the amino acid

sequence set forth in SEQ ID NO:36 or a functional variant or fragment thereof comprising up to 10 amino acid substitutions.

7-12. (canceled)

13. (currently amended) A composition comprising the antibody or antigen-binding fragment thereof as recited in any one of the preceding claims of claim 1.

14. (currently amended) ~~An~~ The composition as recited in claim 13, which is a pharmaceutical composition and further comprises a pharmaceutically acceptable carrier.

15-16. (canceled)

17. (currently amended) A kit comprising: the antibody or antigen-binding fragment thereof as recited in any one of claims ~~1-12~~ according to claim 1.

18-26. (canceled)

27. (previously presented) A method comprising: providing a peptide including a portion of a cell surface receptor that interacts with an activating ligand such as a growth factor to promote cell proliferation, the portion including enough of the cell surface receptor to interact with the activating ligand and the portion; and generating a antibody or antigen-binding fragment thereof

that specifically binds to the peptide.

28-56. (canceled)

57. (currently amended) A method of determining the aggressiveness and/or metastatic potential of a cancer comprising: contacting a sample obtained from a subject having or suspected of having the cancer with an antibody or antigen-binding fragment thereof that specifically binds to a peptide expressed on a cell surface; and determining an amount of the antibody or antigen-binding fragment thereof that specifically binds to the sample.

58. (previously presented) A method as recited in claim 57, wherein the sample comprises cells of the subject and/or a solubilized lysate thereof.

59. (previously presented) A method as recited in claim 57, wherein the peptide includes a portion of a cell surface receptor that interacts with an activating ligand such as a growth factor to promote cell proliferation, the portion including enough of the cell surface receptor to interact with the activating ligand.

60. (previously presented) A method as recited in claim 57, wherein the antibody or antigen-binding fragment thereof is immobilized relative to or adapted to be immobilized relative to a signaling entity.

61. (previously presented) A method as recited in claim 60, wherein the antibody or antigen-

Express Mail Label No.  
**EQ 343742290 US**

Patent  
**13150-70089US**

binding fragment thereof is bivalent.

62. (previously presented) A method as recited in claim 59, wherein the cell surface receptor is MUC1.

63-195. (canceled)